Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus HALOTESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus HALOTESTIN.
ANDROID-F vs HALOTESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Category C
Category C
Androgen/Estrogen Combination
Androgen